TNBC, aggressive and lacking key receptors, complicates treatment, impacting prognosis and requiring specialized approaches.

PR+ breast cancer responds well to hormone therapy, underscoring the need for molecular insight and targeted treatment ...

Pfizer and Arvinas' experimental breast cancer treatment failed to delay the progression of the disease in a broader group of ...

An experimental breast cancer treatment co-developed by Pfizer and Arvinas significantly improved the time some patients ...

Women with breast cancer who receive chemotherapy experienced a lasting decline in physical health, a new study found.

After a long period of annual declines, breast cancer mortality rates for women younger than 40 and older than 74 have ...

Antibody treatment which activates the patient's own immune system against cancer, known as immunotherapy, is increasingly ...

Dr. Chandler Park sat down for an interview with CURE® to discuss the biggest takeaway from the 2025 ASCO GU Symposium in ...

The first patients have been enrolled in the HEROES trial, exploring de-escalation of anti-HER2 therapy in metastatic HER2+ ...

About a quarter of Iowans would no longer pay co-pays and deductibles for supplemental and diagnostic breast exams under ...

Individuals with transportation insecurity appeared 41% less likely to undergo breast cancer screening than those without transportation difficulties, according to results of a cohort study. Alexa L.

Breast cancer mortality rates have stopped declining for women over 74 and under 40, largely due to rising diagnoses of ...